List view / Grid view
The MHRA’s refreshed guidance is the only end-to-end access pathway…
The MHRA’s refreshed guidance is the only end-to-end access pathway that enables medicine developers to collaborate with the national health system, Regulator, and HTA bodies.
The amended regulatory framework will foster clinical trial design innovation…
The amended regulatory framework will foster clinical trial design innovation and provide UK life sciences with faster trial approvals.
The Medicines and Healthcare products Regulatory Agency (MHRA) states its…
The Medicines and Healthcare products Regulatory Agency (MHRA) states its new scheme enables a more streamlined approach to processing Clinical Trial Authorisations (CTAs) for initial applications in late-stage clinical trials.
New recognition routes will facilitate faster and safer access to…
New recognition routes will facilitate faster and safer access to innovative medicines through seven international partners, according to the UK’s MHRA.
The Medicines and Healthcare products Regulatory Agency (MHRA) has launched…
The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on far-reaching proposals to revise the clinical trial legislation in the UK.
The UK regulator confirmed that the Pfizer and AstraZeneca COVID-19…
The UK regulator confirmed that the Pfizer and AstraZeneca COVID-19 vaccines can be used as safe and effective booster doses.
The MHRA has approved the use of the Spikevax vaccine…
The MHRA has approved the use of the Spikevax vaccine (formerly COVID-19 Vaccine Moderna) in children aged 12-17 years old.
The MHRA has given the green light to the Moderna…
The MHRA has given the green light to the Moderna COVID-19 vaccine for use in the UK, making it the third to be approved in the country.
The new pathway developed by NICE for medicines to go…
The new pathway developed by NICE for medicines to go from clinical trials to NHS patients is now in action.
Following reports of the Pfizer/BioNTech COVID-19 vaccine causing anaphylaxis, the…
Following reports of the Pfizer/BioNTech COVID-19 vaccine causing anaphylaxis, the MHRA has said those prone to allergic reaction should not receive the jab.
After evidence suggesting hydroxychloroquine has no benefit against COVID-19, the…
After evidence suggesting hydroxychloroquine has no benefit against COVID-19, the MHRA has suspended further recruitment to clinical trials investigating the drug in the UK.
